The Irish Medicines Board - www.imb.ie

Home
About Us
Consultation
Events
Glossary
Legislation
Links
News
Publications
Recruitment
Register

Safety & Quality
Human Medicines
Veterinary
Medical Devices
Blood, Tissues, Organs
Cosmetics
Patients & Public

Your Selection

[x] Document Type: Direct Healthcare Professional Communication
[x] Remove All Filters

By Product

Human medicines (253)

By Audience / Stakeholder Group

Healthcare professionals (252)
Industry (4)

By Service

Controlled Drugs (2)

Benlysta (belimumab) - Important Safety Information from GlaxoSmithKline as approved by the Irish Medicines Board

09 March 2012

Tags: Human medicines Healthcare professionals Direct Healthcare Professional Communication 2012

Important Safety Information communicatin from GlaxoSmithKline on the association of Benlysta with hypersensitivity and infusion reactions.

Important Safety Information - Benlysta

« View Publications List

Provide Feedback

RSS Feeds

IMB Publications RSS Feed

Date Printed: 23 May 2013

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971